Skip Nav Destination
Contributions to Oncology
Novel Approaches in Anticancer Drug Design: Molecular Modelling - New Treatment Strategies. International Symposium on Novel Approaches in Cacner Therapy, Heidelberg, December 1993Available to Purchase
S.Karger AG
Volume
49
Status:
Available
ISBN electronic:
978-3-318-03432-5
ISBN print:
978-3-8055-6043-6
Discontinued Book Series:
Contributions to Oncology
Publication date:
1995
Novel Approaches in Anticancer Drug Design: Molecular Modelling - New Treatment Strategies. International Symposium on Novel Approaches in Cacner Therapy, Heidelberg, December 1993
Edited by: W.J. Zeller, M. D'Incalci, D.R. Newell
https://doi.org/10.1159/isbn.978-3-318-03432-5
ISBN (print): 978-3-8055-6043-6
ISBN (electronic): 978-3-318-03432-5
Publisher: S.Karger AG
Published: 1995
Download citation file:
Digital Version
Pay-Per-View Access
$194.00
Print Version
Novel Approaches in Anticancer Drug Design
$194.00
Table of Contents
-
1 - 9: Quantum Mechanical Calculations as Aids in Drug DesignByChristopher J. MichejdaChristopher J. MichejdaMolecular Aspects of Drug Design, Macromolecular Structure Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, MD, USASearch for other works by this author on:
-
10 - 15: Molecular Structural Approaches to the Rational Design of New Anticancer AgentsByStephen NeidleStephen NeidleThe CRC Biomolecular Structure Unit at The Institute of Cancer Research, Sutton, Surrey, UKSearch for other works by this author on:
-
16 - 24: Crystal Structure E.coli O6-methyl-guanine-DNA MethyltransferaseByPeter C. E. Moody;Peter C. E. MoodyChemistry Department University of York, York, UKSearch for other works by this author on:Madeleine H. MooreMadeleine H. MooreChemistry Department University of York, York, UKSearch for other works by this author on:
-
25 - 39: A Pseudo-Receptor Model of the Active Site of Protein Kinase C: An Example for a New Technique in Molecular ModellingByC. W. v. d. Lieth;C. W. v. d. LiethaCentral Spectroscopy andSearch for other works by this author on:G. Krauter;G. KrauterbDivision Mechanism of Tumorigenesis, German Cancer Research Center, Heidelberg, GermanySearch for other works by this author on:E. HeckerE. HeckerbDivision Mechanism of Tumorigenesis, German Cancer Research Center, Heidelberg, GermanySearch for other works by this author on:
-
40 - 49: NMR and Molecular Modelling Studies on the Mechanism of Action of the Antitumour Drug TemozolomideByRichard T. Wheelhouse;Richard T. WheelhouseCancer Research Campaign Experimental Cancer Chemotherapy Research Group, Cancer Research Laboratories, University of Nottingham, University Park, Nottingham, EnglandSearch for other works by this author on:Brian J. Denny;Brian J. DennyCancer Research Campaign Experimental Cancer Chemotherapy Research Group, Cancer Research Laboratories, University of Nottingham, University Park, Nottingham, EnglandSearch for other works by this author on:Malcolm F G. StevensMalcolm F G. StevensCancer Research Campaign Experimental Cancer Chemotherapy Research Group, Cancer Research Laboratories, University of Nottingham, University Park, Nottingham, EnglandSearch for other works by this author on:
-
50 - 59: Computer-Assisted Molecular Design as a Guide for Determination of Structure-Activity Relationships for Estrogen Receptor Substrates by Means of a Model Receptor (hα1-Antitrypsin)ByKurt S. Zänker;Kurt S. ZänkerInstitut für Immunologie, Universität Witten/Herdecke, GermanySearch for other works by this author on:Uwe Schmitz;Uwe SchmitzInstitut für Immunologie, Universität Witten/Herdecke, GermanySearch for other works by this author on:Angelika SchwarteAngelika SchwarteInstitut für Immunologie, Universität Witten/Herdecke, GermanySearch for other works by this author on:
-
60 - 65: CrystalGuard: An Automated Crystallisation FacilityByAlexis Nolte;Alexis NolteaInstitut für Biochemie, Freie Universität BerlinSearch for other works by this author on:Siegfried Lorenz;Siegfried LorenzaInstitut für Biochemie, Freie Universität BerlinSearch for other works by this author on:Volker A. Erdmann;Volker A. ErdmannaInstitut für Biochemie, Freie Universität BerlinSearch for other works by this author on:Joachim H. Nuske;Joachim H. NuskebBiometra biomedizinische Analytik GmbH, GöttingenSearch for other works by this author on:Reinhard FurrerReinhard FurrercInstitut für Weltraumwissenschaften, Freie Universität Berlin, Berlin, GermanySearch for other works by this author on:
-
66 - 71: Optimised Sample Preparation for Measurement of Cisplatin-DNA Adducts in White Blood CellsByJ. H. M. Schellens;J. H. M. SchellensLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:J. Verweij;J. VerweijLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:A. S. T. Planting;A. S. T. PlantingLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:M. de Boer-Dennert;M. de Boer-DennertLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:M. E. L. van der Burg;M. E. L. van der BurgLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:G. Stoter;G. StoterLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:J. MaJ. MaLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The NetherlandsSearch for other works by this author on:
-
72 - 80: Modulation of Cisplatin Cytotoxicity by Human Recombinant Gamma-Interferon in Human Ovarian Cancer Cell LinesByAlissar Nehmé;Alissar NehméaGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulousebUniversité Paul Sabatier, Toulouse, FranceSearch for other works by this author on:Nicolas Albin;Nicolas AlbinaGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulouseSearch for other works by this author on:Anne Marie Julia;Anne Marie JuliaaGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulouseSearch for other works by this author on:Suzanne Jozan;Suzanne JozanaGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulousebUniversité Paul Sabatier, Toulouse, FranceSearch for other works by this author on:Roland Bugat;Roland BugataGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulousebUniversité Paul Sabatier, Toulouse, FranceSearch for other works by this author on:Pierre CanalPierre CanalaGroupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, ToulouseSearch for other works by this author on:
-
81 - 87: Dexamethasone-Enhanced Cisplatin Resistance of Human Lung Carcinoma CellsByMagnus von Knebel DoeberitzMagnus von Knebel DoeberitzFSP6 Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, and Department of Internal Medicine — Oncology, Chest Hospital Rohrbach, Heidelberg, GermanySearch for other works by this author on:
-
88 - 94: Cisplatin-Resistant Subline of a Human Ovarian Cancer Cell LineByJ. H. M. Schellens;J. H. M. SchellensLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, Rotterdam, The NetherlandsSearch for other works by this author on:B. B. H. de Bont-Krootjes;B. B. H. de Bont-KrootjesLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, Rotterdam, The NetherlandsSearch for other works by this author on:H. J. Kolker;H. J. KolkerLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, Rotterdam, The NetherlandsSearch for other works by this author on:G. Stoter;G. StoterLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, Rotterdam, The NetherlandsSearch for other works by this author on:J. MaJ. MaLaboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, Rotterdam, The NetherlandsSearch for other works by this author on:
-
95 - 99: Synergistic Interaction between 5-Aza-2’-Deoxycytidine and Cisplatin in Human Ovarian Carcinoma Cell LinesByE. C. Heesbeen;E. C. HeesbeenThe Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for other works by this author on:M. van Vugt;M. van VugtThe Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for other works by this author on:J. H. SchornagelJ. H. SchornagelThe Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for other works by this author on:
-
100 - 108: Pharmacokinetic Study of Orally Administered Ammine Diacetatodichloro(cyclo-hexylamine)platinum IV (JM216) in a 5-Day Dose Schedule Phase I Clinical TrialByF. I. Raynaud;F. I. RaynaudaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:M. J. McKeage;M. J. McKeageaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:J. Ward;J. WardaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:C. Berry;C. BerryaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:D. Odell;D. OdellaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:B. A. Murrer;B. A. MurrerbJohnson Matthey Technology, Reading, UKSearch for other works by this author on:P. Santabárbara;P. SantabárbaracBristol Myers Squibb, Pharmaceutical Research Institute, Wallingford, CT, USASearch for other works by this author on:I. R. Judson;I. R. JudsonaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:K. R. HarrapK. R. HarrapaThe Institute of Cancer Research, Drug Development Section, The Royal Marsden Hospital, Sutton, Surrey, UKSearch for other works by this author on:
-
109 - 116: Identification of Drug Resistance in Fresh Blast Cells from Acute Myeloid Leukaemia and Its Modification in vitroByJean Sargent;Jean SargentDepartment of Haematology, Pembury Hospital, Pembury, Kent, UKSearch for other works by this author on:Alena Elgie;Alena ElgieDepartment of Haematology, Pembury Hospital, Pembury, Kent, UKSearch for other works by this author on:Peter Alton;Peter AltonDepartment of Haematology, Pembury Hospital, Pembury, Kent, UKSearch for other works by this author on:Christine Williamson;Christine WilliamsonDepartment of Haematology, Pembury Hospital, Pembury, Kent, UKSearch for other works by this author on:Colin TaylorColin TaylorDepartment of Haematology, Pembury Hospital, Pembury, Kent, UKSearch for other works by this author on:
-
117 - 123: Chronic in vitro Suramin Exposure Leads to the Development of Drug-Resistant Sublines which Grow as Three-Dimensional Cultures and Are Highly Invasive in vivo. Lack of Growth Factor Involvement in the Cytotoxic Action of the DrugBySophie Lelièvre;Sophie LelièvreDepartment of Structural Biology and Pharmacology, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Villejuif, FranceSearch for other works by this author on:Annette Kragh LarsenAnnette Kragh LarsenDepartment of Structural Biology and Pharmacology, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Villejuif, FranceSearch for other works by this author on:
-
124 - 130: Does TGF β1 Play a Role in Immunosuppression in Small-Cell Lung Cancer?ByJürgen R. Fischer;Jürgen R. FischeraThorax-Klinik der LVA Baden, Department of Medical Oncology, Heidelberg, GermanySearch for other works by this author on:Marianne Schindel;Marianne SchindelaThorax-Klinik der LVA Baden, Department of Medical Oncology, Heidelberg, GermanySearch for other works by this author on:Heidi Darjes;Heidi DarjesaThorax-Klinik der LVA Baden, Department of Medical Oncology, Heidelberg, GermanySearch for other works by this author on:Harald Lahm;Harald LahmbSwiss Institute for Experimental Cancer Research, Department of Cellular Biology, Epalinges, SwitzerlandSearch for other works by this author on:Nicolyn Stein;Nicolyn SteinaThorax-Klinik der LVA Baden, Department of Medical Oncology, Heidelberg, GermanySearch for other works by this author on:Harald Gallati;Harald GallaticHoffmann La Roche, Central Research Unit, Basel, SwitzerlanSearch for other works by this author on:Peter Drings;Peter DringsaThorax-Klinik der LVA Baden, Department of Medical Oncology, Heidelberg, GermanySearch for other works by this author on:Peter H. KrammerPeter H. KrammerdGerman Cancer Research Center, Tumor Immunology Program, Heidelberg, GermanySearch for other works by this author on:
-
131 - 140: Induction Chemotherapy in Stage III Non-Small Cell Lung CancerByC. Manegold;C. ManegoldDepartment of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:J. R. Fischer;J. R. FischerDepartment of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:H. Bülzebruck;H. BülzebruckDepartment of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:I. Vogt-Moykopf;I. Vogt-MoykopfDepartment of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:P. DringsP. DringsDepartment of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:
-
141 - 147: Growth Inhibition and Induction of Differentiation of Human K562 Leukemic Cells by 3′ -Deoxy-3′-Fluorothymidine and Cytosine ArabinosideByPeter Langen;Peter LangenaMax-Delbrück-Centrum für Molekulare Medizin, BerlinSearch for other works by this author on:Klaus Eckert;Klaus EckertbAbteilung für Pharmazeutische Biochemie, Institut für Pharmazie, Freie Universität BerlinSearch for other works by this author on:Tania Fuhrmann-Selter;Tania Fuhrmann-SelterbAbteilung für Pharmazeutische Biochemie, Institut für Pharmazie, Freie Universität BerlinSearch for other works by this author on:Manfred Schütt;Manfred SchüttaMax-Delbrück-Centrum für Molekulare Medizin, BerlinSearch for other works by this author on:H. Rainer MaurerH. Rainer MaurerbAbteilung für Pharmazeutische Biochemie, Institut für Pharmazie, Freie Universität BerlinSearch for other works by this author on:
-
148 - 154: Osteoprotective Potential of Bisphosphonates in Therapy and Prevention of Osteolytic Bone MetastasesByB. Krempien;B. KrempienDepartment of Pathology, University of Heidelberg, and Department of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:Ping Bu;Ping BuDepartment of Pathology, University of Heidelberg, and Department of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:R. Büchele;R. BücheleDepartment of Pathology, University of Heidelberg, and Department of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:C. ManegoldC. ManegoldDepartment of Pathology, University of Heidelberg, and Department of Medical Oncology and Surgery, Thorax-Klinik, Heidelberg, GermanySearch for other works by this author on:
-
155 - 161: DNA Repair Processes and Sensitivity to DNA Damage of Human Lymphocytes and Blasts: Analysis at the Single-Cell LevelByClaudia Buschfort;Claudia BuschfortaInstitute of Cell Biology (Cancer Research) andSearch for other works by this author on:Frank Seiler;Frank SeileraInstitute of Cell Biology (Cancer Research) andSearch for other works by this author on:Mark R. Müller;Mark R. MüllerbDepartment of Internal Medicine, West German Cancer Center, University of Essen Medical School, Essen, GermanySearch for other works by this author on:Siegfried Seeber;Siegfried SeeberbDepartment of Internal Medicine, West German Cancer Center, University of Essen Medical School, Essen, GermanySearch for other works by this author on:Manfred F. Rajewsky;Manfred F. RajewskyaInstitute of Cell Biology (Cancer Research) andSearch for other works by this author on:Jürgen ThomaleJürgen ThomaleaInstitute of Cell Biology (Cancer Research) andSearch for other works by this author on:
-
162 - 166: Sensitization of Animal and Human Ovarian Tumor Cell Lines against BCNU by Inhibition of the O6-alkylguanine-DNA Alkyltransferase with O6-benzylguanineByA. Magull-Seltenreich;A. Magull-SeltenreichaGerman Cancer Research Center, Division 0420, Heidelberg, GermanySearch for other works by this author on:A. Skrotzki;A. SkrotzkiaGerman Cancer Research Center, Division 0420, Heidelberg, GermanySearch for other works by this author on:N. Frank;N. FrankbGerman Cancer Research Center, Division 0330, Heidelberg, GermanySearch for other works by this author on:W. J. ZellerW. J. ZelleraGerman Cancer Research Center, Division 0420, Heidelberg, GermanySearch for other works by this author on:
-
167 - 178: Synthesis, Properties and Potential Mechanism of Action of Fused Pyrazine mono-N-Oxide Bioreductive DrugsByM. A. NaylorM. A. NaylorDepartment of Medicinal Chemistry, Division of Experimental Oncology, MRC Radiobiology Unit, Chilton, Oxon (UK)Search for other works by this author on:
-
179 - 186: Synthesis and Preliminary 11B NMR Biodistribution Studies of Nitroimidazole-Carboranes Designed for Boron Neutron Capture TherapyByMichael D. Threadgill;Michael D. ThreadgillaSchool of Pharmacy & Pharmacology, University of Bath, Claverton Down, BathSearch for other works by this author on:Martin Scobie;Martin ScobieaSchool of Pharmacy & Pharmacology, University of Bath, Claverton Down, BathSearch for other works by this author on:Pauline J. Wood;Pauline J. WoodbMedical Research Council Radiobiology Unit, Chilton, Didcot, Oxfordshire, UKSearch for other works by this author on:Sean P. BewSean P. BewaSchool of Pharmacy & Pharmacology, University of Bath, Claverton Down, BathSearch for other works by this author on:
-
187 - 191: Activity of Steroid-Linked Nitrosoureas in a Cell Line Derived from Human MeningiomaByF. J. H. Taut;F. J. H. TautaGerman Cancer Research Center, HeidelbergSearch for other works by this author on:B. Muβler;B. MuβlerbDepartment of Food Chemistry and Environmental Toxicology, University of KaiserslauternSearch for other works by this author on:M. B. Jager;M. B. JagerbDepartment of Food Chemistry and Environmental Toxicology, University of KaiserslauternSearch for other works by this author on:G. Eisenbrand;G. EisenbrandbDepartment of Food Chemistry and Environmental Toxicology, University of KaiserslauternSearch for other works by this author on:B. Wowra;B. WowracDepartment of Neurosurgery, University of Heidelberg, GermanySearch for other works by this author on:W. J. ZellerW. J. ZelleraGerman Cancer Research Center, HeidelbergSearch for other works by this author on:
